Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea · Delayed Price · Currency is KRW 57,400
+1,200 (2.14%)
At close: Mar 18, 2026
Hanall Biopharma Revenue
In the year 2025, Hanall Biopharma had annual revenue of 155.18B KRW with 11.69% growth. Hanall Biopharma had revenue of 37.55B in the quarter ending December 31, 2025, with 3.11% growth.
Revenue
155.18B
Revenue Growth
+11.69%
P/S Ratio
18.78
Revenue / Employee
510.48M
Employees
304
Market Cap
2.91T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 155.18B | 16.24B | 11.69% |
| Dec 31, 2024 | 138.94B | 4.03B | 2.99% |
| Dec 31, 2023 | 134.91B | 24.91B | 22.65% |
| Dec 31, 2022 | 110.00B | 8.40B | 8.27% |
| Dec 31, 2021 | 101.59B | 12.99B | 14.66% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Yuhan | 2.14T |
| Daewoong | 2.07T |
| GC Biopharma | 1.93T |
| Chong Kun Dang Pharmaceutical | 1.68T |
| Daewoong Pharmaceutical | 1.54T |
| Hanmi Pharm. | 1.47T |
| Boryung | 1.03T |
| DongKook Pharmaceutical | 894.93B |